Drug profile · INN
rivastigmine
EXELON
rivastigmine (EXELON) is a cholinesterases; ache & bche inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: transdermal. Current US regulatory status: approved.
Drug details — rivastigmine
- US status
- approved
- Class
- Nervous system (N06)
- Route
- TRANSDERMAL
- Patents
- 2
- Programs
- 4
- Data quality
- 0.89
Quick answer
rivastigmine (EXELON) is a cholinesterases; ache & bche inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: transdermal. Current US regulatory status: approved.
Key facts
Mechanism of action
Cholinesterases; ACHE & BCHE inhibitor
Primary target: Cholinesterases; ACHE & BCHE
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is rivastigmine?
rivastigmine (EXELON) is a cholinesterases; ache & bche inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: transdermal. Current US regulatory status: approved.
What is the brand name for rivastigmine?
EXELON is a marketed brand name for rivastigmine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rivastigmine?
rivastigmine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.